Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies
Cancer Treatment Reviews · 2024-09 · 129 · 102808
DOI: 10.1016/j.ctrv.2024.102808 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024-09. Verfasst von Ji-Hoon Lee. Beteiligte Einrichtung: Department of Biological Sciences, Research Center of Ecomimetics, Chonnam National University, Gwangju 61186, Republic of Korea. Electronic address:…. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, Neoplasms, Precision Medicine. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 237 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chonnam National University, Ministry of Science, ICT and Future Planning, National Research Foundation of Korea.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Research Center of Ecomimetics, Chonnam National University, Gwangju 61186, Republic of Korea. Electronic address: microljh@jnu.ac.kr.
Förderung
- Chonnam National University
- Ministry of Science, ICT and Future Planning
- National Research Foundation of Korea
- Korea Ministry of Science and ICT
Zitieren
APA
Lee, J. H. (2024). Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies. Cancer Treatment Reviews, 129, 102808. https://doi.org/10.1016/j.ctrv.2024.102808
Vancouver
Lee JH. Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies. Cancer Treatment Reviews. 2024;129:102808. doi:10.1016/j.ctrv.2024.102808
BibTeX
@article{Lee2024,
author = {Lee, Ji-Hoon},
title = {Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies},
journal = {Cancer Treatment Reviews},
year = {2024},
volume = {129},
pages = {102808},
doi = {10.1016/j.ctrv.2024.102808}
}
EUVIMED